Biochemical alterations and paraneoplasic syndromes in patients with renal carcinoma

Authors

DOI:

https://doi.org/10.48193/nfqbtm59

Keywords:

renal carcinoma, biochemical alterations, paranoeplasic syndromes

Abstract

Introduction: Renal carcinoma can show biochemical and paraneoplasic alterations at the moment of its diagnosis. Its diagnosis can be delayed due to these biochemical alterations. About 20 % of patients with renal carcinoma can have paraneoplasic syndromes or biochemical alterations.

 

Method: We reviewed the information of patients treated with nephrectomy for renal cell carcinoma between 2015 and 2022. We analyzed demographic, clinical and oncological variables. We performed a retrospective, descriptive, analytical study.

 

Results: We reviewed 65 files. Prevalence in males was higher with 72.3 %. Age mean was 66 years. Renal cell carcinoma was found in 70 % of patients. 34.4 % presented with anemia, LDH was elevated in 9.5 %. Hypercalcemia presented in 7.8 %. GGT was elevated in 21.4 %. Alcaline phosphatase was elevated in 29.2 %. 13 % showed hipoalbuminemia. Globular sedimentation rate was high in 75 %. Prothrombin time was high in 9.1 %. Neutrophil-lymphocyte ratio (NLR) was high in 33 %.

Conclusions: Renal carcinoma is a pathology that can show biochemical alterations and different paraneoplasic syndromes. Diagnosis and management must be individualized. Mexican population shows similar biochemical alterations compared to the data reported in international literature.

Author Biographies

  • Fernanda Monserrat Badillo-Silva, Universidad Nacional Autónoma de México, Ciudad de México, México.

    Estudiante de la carrera de m´´edico cirujano.

  • Álvaro Reyes-Acquart, Instituto de Seguridad y Servicios Sociales para los Trabajadores del Estado, Hospital Regional Lic. Adolfo López Mateos, Ciudad de México, México.

    Medical student in León, Guanajuato. Resident of urology. 

References

Linehan WM, Ricketts CJ. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nature Reviews Urology. 2019;16(9): 539–552. https://doi.org/10.1038/s41585-019-0211-5.

Kim HL, Belldegrun AS, Freitas DG, Bui MHT, Han KR, Dorey FJ, et al. Paraneoplastic Signs and Symptoms of Renal Cell Carcinoma: Implications for Prognosis. Journal of Urology. 2003;170(5): 1742–1746. https://doi.org/10.1097/01.ju.0000092764.81308.6a.

Palapattu GS, Kristo B, Rajfer J. Paraneoplastic Syndromes in Urologic Malignancy: The Many Faces of Renal Cell Carcinoma. Reviews in Urology. 2002;4(4): 163–170.

Muggia FM. Overview of cancer-related hypercalcemia: epidemiology and etiology. Seminars in Oncology. 1990;17(2 Suppl 5): 3–9.

Mundy GR, Ibbotson KJ, D’Souza SM, Simpson EL, Jacobs JW, Martin TJ. The Hypercalcemia of Cancer: Clinical Implications and Pathogenic Mechanisms. Flier JS, Moore MJ (eds.) New England Journal of Medicine. 1984;310(26): 1718–1727. https://doi.org/10.1056/nejm198406283102607.

Chasan SA, Pothel LR, Huben RE. Management and prognostic significance hypercalcemia in renal cell carcinoma. Urology. 1989;33(3): 167–170. https://doi.org/10.1016/0090-4295(89)90383-x.

Dahl T, Eide I, Fryjordet A. Hypernephroma and Hypertension. Acta Medica Scandinavica. 1981;209(1–6): 121–124. https://doi.org/10.1111/j.0954-6820.1981.tb11563.x.

Lindop GB, Fleming S. Renin in renal cell carcinoma--an immunocytochemical study using an antibody to pure human renin. Journal of Clinical Pathology. 1984;37(1): 27–31. https://doi.org/10.1136/jcp.37.1.27.

Kirchner FK, Braren V, Smith C, Wilson JP, Foster JH, Hollifield JW, et al. Renal Carcinoma Discovered Incidentally by Arteriography During Evaluation for Hypertension. Journal of Urology. 1976;115(6): 643–645. https://doi.org/10.1016/s0022-5347(17)59319-2.

Maldonado JE, Sheps SG, Bernatz PE, DeWeerd JH, Harrison EG. Renal arteriovenous fistula. The American Journal of Medicine. 1964;37(4): 499–513. https://doi.org/10.1016/0002-9343(64)90064-6.

Sufrin G, Mirand EA, Moore RH, Chu TM, Murphy GP. Hormones in renal cancer. Transactions of the American Association of Genito-Urinary Surgeons. 1976;68: 115–120.

Kranidiotis GP, Voidonikola PT, Dimopoulos MK, Anastasiou-Nana MI. Stauffer’s syndrome as a prominent manifestation of renal cancer: a case report. Cases Journal. 2009;2(1): 49. https://doi.org/10.1186/1757-1626-2-49.

Tanous B, Alsaud A, Mahmoud KE, Yassin MA. A Rare Presentation of Stauffer’s Syndrome Associated with Renal Cell Carcinoma. Case Reports in Oncology. 2020;13(2): 742–746. https://doi.org/10.1159/000508039.

Tashjian AH. Prostaglandins, Hypercalcemia and Cancer. New England Journal of Medicine. 1975;293(25): 1317–1318. https://doi.org/10.1056/nejm197512182932511.

Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Négrier S, et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. International Journal of Cancer. 1997;72(3): 424–430. https://doi.org/10.1002/(sici)1097-0215(19970729)72:3<424::aid-ijc9>3.0.co;2-r.

Ikuerowo S, Ojewuyi O, Omisanjo O, Abolarinwa A, Bioku M, Doherty A. Paraneoplastic syndromes and oncological outcomes in renal cancer. Nigerian Journal of Clinical Practice. 2019;22(9): 1271. https://doi.org/10.4103/njcp.njcp_35_19.

Fichman M, Bethune J. Effects of neoplasms on renal electrolyte function. Annals of the New York Academy of Sciences. 1974;230(1): 448–472. https://doi.org/10.1111/j.1749-6632.1974.tb14479.x.

Strum WB. Remote recurrence of renal cell carcinoma. Urology. 1984;23(1): 68–70. https://doi.org/10.1016/0090-4295(84)90181-x.

Downloads

Published

2024-04-06

Issue

Vol. 84 No. 1 (2024): January-February

Section

Original articles

License

Copyright (c) 2024 Revista Mexicana de Urología

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.